Atelvia
Osteoporosis, Malignant Neoplasms, Postmenopause + 3 more
Treatment
5 FDA approvals
20 Active Studies for Atelvia
Treatment for
Osteoporosis
What is Atelvia
Risedronic acid
The Generic name of this drug
Treatment Summary
Risedronic acid is a medication used to prevent bone loss and the weakening of bones caused by conditions such as osteoporosis and Paget’s disease. It is a type of bisphosphonate, a form of drug that works by blocking the removal of bone cells.
Actonel
is the brand name
Atelvia Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Actonel
Risedronic acid
1998
61
Approved as Treatment by the FDA
Risedronic acid, also called Actonel, is approved by the FDA for 5 uses including Therapeutic procedure and Paget’s Disease .
Therapeutic procedure
Paget’s Disease
Bone and Bones
Used to treat increased bone mass in combination with Calcium
Osteoporosis
Used to treat Osteoporosis in combination with Calcium
Postmenopause
Effectiveness
How Atelvia Affects Patients
Risedronate is a medicine that helps prevent bones from being broken down by blocking the activity of cells called osteoclasts.
How Atelvia works in the body
Risedronatic acid binds to the bones and stops cells that break down bones, called osteoclasts, from doing their job. It does this by entering the cells, becoming acidic, and then inhibiting an enzyme called farnesyl pyrophosphate synthase. This stops the osteoclast from breaking down the bones, which decreases bone resorption.
When to interrupt dosage
The proposed dose of Atelvia is contingent upon the recognized condition, including Therapeutic procedure, Malignant Neoplasms and Postmenopause. The measure fluctuates as per the technique of delivery, as detailed in the table beneath.
Condition
Dosage
Administration
Bone and Bones
30.0 mg, , 5.0 mg, 35.0 mg, 150.0 mg, 75.0 mg, 129.0 mg, 4.9 mg, 30.1 mg, 64.5 mg, 4.3 mg, 25.8 mg
, Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Granule, effervescent; Kit; Tablet, Granule, effervescent; Kit; Tablet - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Delayed Release - Oral, Tablet, Delayed Release, Kit; Tablet, Kit; Tablet - Oral, Kit
Osteoporosis
30.0 mg, , 5.0 mg, 35.0 mg, 150.0 mg, 75.0 mg, 129.0 mg, 4.9 mg, 30.1 mg, 64.5 mg, 4.3 mg, 25.8 mg
, Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Granule, effervescent; Kit; Tablet, Granule, effervescent; Kit; Tablet - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Delayed Release - Oral, Tablet, Delayed Release, Kit; Tablet, Kit; Tablet - Oral, Kit
Malignant Neoplasms
30.0 mg, , 5.0 mg, 35.0 mg, 150.0 mg, 75.0 mg, 129.0 mg, 4.9 mg, 30.1 mg, 64.5 mg, 4.3 mg, 25.8 mg
, Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Granule, effervescent; Kit; Tablet, Granule, effervescent; Kit; Tablet - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Delayed Release - Oral, Tablet, Delayed Release, Kit; Tablet, Kit; Tablet - Oral, Kit
Postmenopause
30.0 mg, , 5.0 mg, 35.0 mg, 150.0 mg, 75.0 mg, 129.0 mg, 4.9 mg, 30.1 mg, 64.5 mg, 4.3 mg, 25.8 mg
, Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Granule, effervescent; Kit; Tablet, Granule, effervescent; Kit; Tablet - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Delayed Release - Oral, Tablet, Delayed Release, Kit; Tablet, Kit; Tablet - Oral, Kit
Therapeutic procedure
30.0 mg, , 5.0 mg, 35.0 mg, 150.0 mg, 75.0 mg, 129.0 mg, 4.9 mg, 30.1 mg, 64.5 mg, 4.3 mg, 25.8 mg
, Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Granule, effervescent; Kit; Tablet, Granule, effervescent; Kit; Tablet - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Delayed Release - Oral, Tablet, Delayed Release, Kit; Tablet, Kit; Tablet - Oral, Kit
Paget’s Disease
30.0 mg, , 5.0 mg, 35.0 mg, 150.0 mg, 75.0 mg, 129.0 mg, 4.9 mg, 30.1 mg, 64.5 mg, 4.3 mg, 25.8 mg
, Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, Tablet - Oral, Granule, effervescent; Kit; Tablet, Granule, effervescent; Kit; Tablet - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, Delayed Release - Oral, Tablet, Delayed Release, Kit; Tablet, Kit; Tablet - Oral, Kit
Warnings
Atelvia has three contraindications, so it ought not be administered when encountering any of the circumstances outlined in the following table.
Atelvia Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Risedronic Acid may interact with Pulse Frequency
Hypocalcemia
Do Not Combine
Postural Orthostatic Tachycardia Syndrome
Do Not Combine
There are 20 known major drug interactions with Atelvia.
Common Atelvia Drug Interactions
Drug Name
Risk Level
Description
Etidronic acid
Minor
The risk or severity of adverse effects can be increased when Risedronic acid is combined with Etidronic acid.
Incadronic acid
Minor
The risk or severity of adverse effects can be increased when Risedronic acid is combined with Incadronic acid.
Tiludronic acid
Minor
The risk or severity of adverse effects can be increased when Risedronic acid is combined with Tiludronic acid.
Acipimox
Moderate
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Risedronic acid is combined with Acipimox.
Aluminium clofibrate
Moderate
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Risedronic acid is combined with Aluminium clofibrate.
Atelvia Toxicity & Overdose Risk
Ten percent of people taking this drug have reported experiencing back pain, joint pain, stomach pain, and indigestion. Other rare side effects include swelling of the face, skin rashes, eye irritation, and inflammation of the uvea. If someone takes too much of this drug, they may have reduced levels of calcium and phosphorus in their blood. Treatment options include drinking milk or taking antacids to bind the drug and reduce absorption. In more serious cases, a doctor may need to give the patient their stomach contents or intravenous calcium. A single overdose of this drug in rats was found to be 320 to 620 times the
Atelvia Novel Uses: Which Conditions Have a Clinical Trial Featuring Atelvia?
Fifty active trials are being conducted to assess the potential of Atelvia to treat Paget's Disease, Postmenopause and Malignant Neoplasms.
Condition
Clinical Trials
Trial Phases
Postmenopause
4 Actively Recruiting
Phase 2, Not Applicable
Therapeutic procedure
0 Actively Recruiting
Paget’s Disease
0 Actively Recruiting
Bone and Bones
0 Actively Recruiting
Malignant Neoplasms
0 Actively Recruiting
Osteoporosis
28 Actively Recruiting
Not Applicable, Phase 4, Phase 1, Phase 3, Phase 2
Atelvia Reviews: What are patients saying about Atelvia?
5
Patient Review
11/10/2014
Atelvia for Decreased Bone Mass Following Menopause
5
Patient Review
3/27/2015
Atelvia for Osteoporosis
4.7
Patient Review
10/8/2014
Atelvia for Osteoporosis
4
Patient Review
9/22/2014
Atelvia for Osteoporosis
3
Patient Review
12/6/2013
Atelvia for Decreased Bone Mass Following Menopause
2.3
Patient Review
11/18/2014
Atelvia for Osteoporosis
2
Patient Review
10/3/2015
Atelvia for Osteoporosis
2
Patient Review
5/15/2015
Atelvia for Osteoporosis
1.7
Patient Review
10/25/2013
Atelvia for Osteoporosis
1.7
Patient Review
7/8/2014
Atelvia for Osteoporosis
1.7
Patient Review
7/14/2014
Atelvia for Post-Menopausal Osteoporosis Prevention
1.7
Patient Review
2/22/2014
Atelvia for Osteoporosis
1.7
Patient Review
4/14/2014
Atelvia for Osteoporosis
1.3
Patient Review
2/25/2014
Atelvia for Decreased Bone Mass Following Menopause
1.3
Patient Review
5/6/2014
Atelvia for Decreased Bone Mass Following Menopause
1
Patient Review
1/30/2014
Atelvia for Decreased Bone Mass Following Menopause
1
Patient Review
5/31/2017
Atelvia for Decreased Bone Mass Following Menopause
1
Patient Review
5/6/2014
Atelvia for Osteoporosis
Patient Q&A Section about atelvia
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
How often do you take Atelvia?
"Atelvia may be used to treat osteoporosis in postmenopausal women. It is a delayed-release tablet that is taken once a week."
Answered by AI
What is Atelvia used for?
"Atelvia is a prescription medication used to treat osteoporosis in postmenopausal women. The longevity of Atelvia's efficacy is unknown. You should consult your physician periodically to see if Atelvia is still an appropriate medication for you."
Answered by AI
How long can you take Atelvia?
"Do as your doctor says when taking Atelvia. This includes following directions on the prescription label and reading all medication guides or instruction sheets. Your doctor may sometimes change your dose of the medication. Risedronate is commonly only taken for 3 to 5 years."
Answered by AI